Actively Recruiting
Long-term Safety Observation of Autologous Cardiac Stem Cells JRM-001 in Children with Congenital Heart Disease After Reconstructive Surgery
Led by Metcela Inc. · Updated on 2026-10-20
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to investigate the long-term safety of autologous cardiac stem cells called JRM-001 in children with single ventricle heart conditions, including Hypoplastic Left Heart Syndrome HLHS. The study focuses on patients who previously participated in a trial evaluating the use of JRM-001 after reconstructive heart surgery. The goal is to monitor safety outcomes over one year following treatment. Participants include two groups those who received the JRM-001 stem cells after a catheter examination, and those who had only the catheter examination without receiving JRM-001. This observational study does not involve new treatments but monitors patients based on their prior participation in the earlier trial. Participants will be observed for 12 months to track any adverse events or serious adverse events. During the study, researchers will collect information about any side effects or serious health issues that occur from enrollment through the 12-month period. Participants medical data will be reviewed to assess safety, and visits to the clinical trial site are required for monitoring. The study is sponsored by Metcela Inc. and is expected to be completed by February 2030.
CONDITIONS
Brief Title
Long-term Safety Study Following to JRM-001 Treatment in Pediatric Patients With Congenital Heart Disease
Research Team
C
Clinical Trial Inquiry Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here